FDA Approves Genentech ’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors

South San Francisco, CA -- October 4, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news